Compare Illumina, Inc. (ILMN) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs LyondellBasell Industries NV — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while LyondellBasell Industries NV trades at $63.98 (market cap $20.24B). The key difference: Illumina, Inc. is the larger of the two by market cap, and LyondellBasell Industries NV pays a 6.58% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | LYB | |
|---|---|---|
Market Cap | $28.96B | $20.24B |
Sector | Health | Basic Materials |
52-Week High | $205.10 | $82.38 |
52-Week Low | $91.00 | $42.28 |
Enterprise Value | $30.32B | $31.83B |
Dividend Yield | — | 6.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
LyondellBasell Industries (LYB) trades at $59.595, down 2.97% on the day, with a bearish technical signal. The company reported a strong Q2 2026 earnings beat ($4.30 EPS vs. $3.44 expected) but faces declining revenue and negative net income margins. Recent news highlights supply disruptions supporting margins, while analyst consensus is a Buy with a $70.56 price target, implying 18% upside.
Outlook is mixed: earnings momentum and undervaluation (P/S 0.62) offer opportunity, but weak profitability and high debt pose risks. The stock's direction hinges on margin sustainability and broader economic conditions affecting chemical demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
